BR112018002681A2 - ?composto, composição, e, método para tratamento de infecção por hiv? - Google Patents
?composto, composição, e, método para tratamento de infecção por hiv?Info
- Publication number
- BR112018002681A2 BR112018002681A2 BR112018002681A BR112018002681A BR112018002681A2 BR 112018002681 A2 BR112018002681 A2 BR 112018002681A2 BR 112018002681 A BR112018002681 A BR 112018002681A BR 112018002681 A BR112018002681 A BR 112018002681A BR 112018002681 A2 BR112018002681 A2 BR 112018002681A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- composition
- hiv infection
- treating hiv
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
são descritos compostos de fórmula (i), incluindo sais farmaceuticamente aceitáveis, composições farmacêuticas compreendendo os compostos, métodos para produzir os compostos e seu uso na inibição de integrasse hiv e tratamento daqueles infectados por hiv ou aids.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562202973P | 2015-08-10 | 2015-08-10 | |
PCT/IB2016/054827 WO2017025913A1 (en) | 2015-08-10 | 2016-08-10 | Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018002681A2 true BR112018002681A2 (pt) | 2019-04-24 |
Family
ID=56851648
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018002681A BR112018002681A2 (pt) | 2015-08-10 | 2016-08-10 | ?composto, composição, e, método para tratamento de infecção por hiv? |
Country Status (12)
Country | Link |
---|---|
US (1) | US10138253B2 (pt) |
EP (1) | EP3334741A1 (pt) |
JP (1) | JP2018522924A (pt) |
KR (1) | KR20180035908A (pt) |
CN (1) | CN108026113A (pt) |
AU (1) | AU2016305338A1 (pt) |
BR (1) | BR112018002681A2 (pt) |
CA (1) | CA2994517A1 (pt) |
IL (1) | IL257155A (pt) |
RU (1) | RU2018106494A (pt) |
WO (1) | WO2017025913A1 (pt) |
ZA (1) | ZA201800657B (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109232562A (zh) * | 2018-10-24 | 2019-01-18 | 康化(上海)新药研发有限公司 | 一种7-氮杂吲哚-5-氯-6-羧酸的合成方法 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040041177A (ko) | 2001-09-26 | 2004-05-14 | 바이엘 파마슈티칼스 코포레이션 | 당뇨병 치료제로서의 1,6-나프티리딘 유도체 |
US7939545B2 (en) | 2006-05-16 | 2011-05-10 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
BRPI0819328A8 (pt) | 2007-11-15 | 2016-02-10 | Boehringer Ingelheim Int | Compostos inibidores de replicação de vírus da imunodeficiência humana, composição farmacêutica e uso dos ditos compostos |
ATE541841T1 (de) | 2007-11-15 | 2012-02-15 | Boehringer Ingelheim Int | Inhibitoren der replikation des human immunodeficiency virus |
EP2220046B1 (en) | 2007-11-16 | 2014-06-18 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
JP5269087B2 (ja) | 2007-11-16 | 2013-08-21 | ギリアード サイエンシス インコーポレーテッド | ヒト免疫不全ウイルス複製のインヒビター |
GB0908394D0 (en) | 2009-05-15 | 2009-06-24 | Univ Leuven Kath | Novel viral replication inhibitors |
US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
GB0913636D0 (en) | 2009-08-05 | 2009-09-16 | Univ Leuven Kath | Novel viral replication inhibitors |
US20120316161A1 (en) | 2009-12-23 | 2012-12-13 | Katholieke Universiteit Leuven | Novel antiviral compounds |
US8633200B2 (en) | 2010-09-08 | 2014-01-21 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
US8629276B2 (en) | 2012-02-15 | 2014-01-14 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
US9034882B2 (en) | 2012-03-05 | 2015-05-19 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
US8906929B2 (en) * | 2012-08-16 | 2014-12-09 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
WO2014164467A1 (en) | 2013-03-13 | 2014-10-09 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
WO2014164409A1 (en) * | 2013-03-13 | 2014-10-09 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
US9527842B2 (en) | 2013-03-14 | 2016-12-27 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
US9409922B2 (en) * | 2014-02-18 | 2016-08-09 | Bristol-Myers Squibb Company | Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication |
US9193720B2 (en) | 2014-02-20 | 2015-11-24 | Bristol-Myers Squibb Company | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
-
2016
- 2016-08-10 BR BR112018002681A patent/BR112018002681A2/pt not_active Application Discontinuation
- 2016-08-10 RU RU2018106494A patent/RU2018106494A/ru not_active Application Discontinuation
- 2016-08-10 KR KR1020187006638A patent/KR20180035908A/ko unknown
- 2016-08-10 JP JP2018506991A patent/JP2018522924A/ja active Pending
- 2016-08-10 CN CN201680050389.8A patent/CN108026113A/zh active Pending
- 2016-08-10 US US15/749,158 patent/US10138253B2/en not_active Expired - Fee Related
- 2016-08-10 EP EP16758280.8A patent/EP3334741A1/en not_active Withdrawn
- 2016-08-10 AU AU2016305338A patent/AU2016305338A1/en not_active Abandoned
- 2016-08-10 WO PCT/IB2016/054827 patent/WO2017025913A1/en active Application Filing
- 2016-08-10 CA CA2994517A patent/CA2994517A1/en not_active Abandoned
-
2018
- 2018-01-25 IL IL257155A patent/IL257155A/en unknown
- 2018-01-31 ZA ZA2018/00657A patent/ZA201800657B/en unknown
Also Published As
Publication number | Publication date |
---|---|
US10138253B2 (en) | 2018-11-27 |
CA2994517A1 (en) | 2017-02-16 |
US20180230165A1 (en) | 2018-08-16 |
CN108026113A (zh) | 2018-05-11 |
ZA201800657B (en) | 2019-07-31 |
WO2017025913A1 (en) | 2017-02-16 |
EP3334741A1 (en) | 2018-06-20 |
JP2018522924A (ja) | 2018-08-16 |
AU2016305338A1 (en) | 2018-03-01 |
IL257155A (en) | 2018-03-29 |
RU2018106494A (ru) | 2019-09-12 |
KR20180035908A (ko) | 2018-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017022544A2 (pt) | ?composto, composição, e, método para tratamento de infecção por hiv?. | |
EA201890425A1 (ru) | Противовирусные фосфодиамидные сложноэфирные бета-аминокислотные соединения | |
UY37710A (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
BR112018005904A2 (pt) | composto, e, método de prevenção e/ou tratamento do hiv. | |
EA201790389A1 (ru) | Пирролопиримидиновые соединения, используемые в качестве агониста tlr7 | |
BR112018005870A2 (pt) | composto, e, método de prevenção e/ou tratamento do hiv. | |
CL2016002179A1 (es) | Nuevas heteroarildihidropirimidinas 6-fusionadas para el tratamiento y la profilaxis de la infección por virus de la hepatitis b. | |
BR112018002689A2 (pt) | composto, composição útil e método para tratamento de infecção por hiv | |
NZ733174A (en) | Quinazoline derivatives used to treat hiv | |
BR112017011941A2 (pt) | compostos 5-amino-6h-tiazol [4,5-d] pirimidina-2,7-diona substituídos 3 para o tratamento e profilaxia de infecção viral | |
BR112018077015A2 (pt) | derivados de ácido borônico e usos terapêuticos dos mesmos | |
BR112015021027A8 (pt) | compostos terapêuticos, seus usos, e composições farmacêuticas | |
EA201792069A1 (ru) | Производные азокана и азонана и способы лечения инфекций гепатита в | |
EA201791515A1 (ru) | Соединения пиразина для лечения инфекционных заболеваний | |
BR112014018990A8 (pt) | Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção | |
EA201891063A1 (ru) | Производные дигидроимидазопиразинона, применимые в лечении рака | |
EA201590674A1 (ru) | Производные 5-фенокси-3h-пиримидин-4-она и их применение в качестве ингибиторов обратной транскрипазы вич | |
BR112018013251A2 (pt) | compostos heterocílicos tricíclicos fundidos como inibidores da hiv integrase | |
EA201690687A1 (ru) | Ингибиторы репликации вируса иммунодефицита | |
CU20170109A7 (es) | Derivado de quinoleina para tratar y prevenir infecciones virales | |
NZ733125A (en) | Isoquinoline compounds for the treatment of hiv | |
BR112017028456A2 (pt) | composto, e, método de prevenção e/ou tratamento de hiv | |
BR112017000246A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal | |
BR112017004153A2 (pt) | métodos para tratamento de infecções por protozoários | |
BR112016016854A2 (pt) | Derivados de 7-oxo-1,6-diazabiciclo[3.2.1]octana, seu processo de preparação e seu uso, composição farmacêutica e seu uso pedidos de patente relacionados |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |